Whether or not it is
At the recent 6th Annual Digital Pharma East conference in Philadelphia, Bill Drummy, CEO of HeartBeat Ideas, argued that 'With digital you can get way more bang for your buck, so you HAVE to think of the digital channel.' Drummy's message was simple: the ROI of online promotion is an order of magnitude greater than the "typical" 2:1 ROI for non-digital channel promotion. This may be true of small budget campiagns, but is it scaleable to the point where digital promotion gives you a significant bump in sales?
Mobile is the new 'shiny thing' of interest to pharmaceutical marketers. However, most pharma mobile apps that I have seen are pretty mundane as far as marketing/advertising is concerned. What's it going to take to make these apps more interesting and useful?
This article reviews two recently published and important guidances from the FDA that concern the dissemination of drug information to consumers.
Welcome to Volume 10, Issue #13 (23 AUGUST 2011) of Pharma Marketing News.
Drugmakers dissatisfied with the FDA's use of guidances as a form of policymaking -- including long-awaited guidance for use of social media by the pharmaceutical industry -- could find legal ammunition against the practice. This article presents the relevant case information.
'Just when we are overrun with the need for content & media strategies of every type from search to email to website to video to social to mobile, now we have the opportunity to contemplate an infographics strategy,' said Craig DeLarge, Director, Healthcare Professional Relationship Marketing at Novo Nordisk. Infographics have found a home on Pinterest, a content sharing, social media service that allows members to 'pin' images, videos and other objects to thematic pin boards.
There are enough legal issues in this case to keep a boatload of constitutional and pharma lawyers busy for years. But let's look at this from a different perspective -- i.e., what pharma has to gain from this and what patients have to lose.
Unless taken, medicines don't work. Lack of medication adherence is a major issue contributing to poor health outcomes and higher costs. HealthPrize Technologies believes it has at least part of the solution, which is to provide an innovative approach with an online and mobile-based program that is fun, engaging and educational. This article summarizes the results of a six-month asthma and chronic obstructive pulmonary disease (COPD) pilot study in which HealthPrize partnered with RealAge to test patient engagement with the HealthPrize online and mobile platform.
In this review of presentations made at the the PharmaMarketing Summit 2012, the common thread throughout is the evolving nature of the pharma-physician relationship, which is being transformed by the power of patients and payers, particularly aided and abetted by new emerging technologies.